Screening for Future Vaccine and Antibody Studies
This study is looking for healthy volunteers to see if they might be eligible for future clinical trials at the National Institute of Allergy and Infectious Diseases (NIAID). These future trials will test investigational vaccines and monoclonal antibodies (lab-made proteins that act like human antibodies). The main goal of this screening study is to identify people who can safely participate in these other trials. Researchers also want to understand how different factors might affect who can join specific early-stage trials. You can join if you are between 18 and 60 years old, willing to give blood and/or tissue samples, and don't have a condition where repeated blood draws or injections would be too risky.
- Study design
- This is an observational study, meaning researchers will gather information without giving any specific treatments. It aims to enroll about 4000 participants.
- What's involved
- You would need to agree to have blood and/or tissue samples collected and stored for future studies.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint (what the study measures) is ongoing screening for eligibility.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Screening Volunteers for Clinical Trials
At a glance
Conditions
NCT01375530
Where you'd take part
This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
National Institutes of Health Clinical Center
Bethesda, Marylandstudy coordinator listed
Recruiting
Emory University
Atlanta, Georgiano site contact published
Completed
Univ of MD School of Medicine Center for Vaccine Development & Global Health
Baltimore, Marylandno site contact published
Active, not recruiting
University of Pennsylvania-UPenn
Philadelphia, Pennsylvaniano site contact published
Completed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Lasonji A Holman, C.R.N.P. · PRINCIPAL_INVESTIGATOR · National Institute of Allergy and Infectious Diseases (NIAID)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To screen subjects for their eligibility to participate in clinical trials.Ongoing
Duration of subject participation is variable, and may last from a few weeks to several months for each subject.